Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu177-dotatate in recurrent meningioma
IRCT20190623043986N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jun 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in meningioma, sponsored by Shiraz University of Medical Sciences. Primary endpoints: Response to therapy based on MRI findings, Response to therapy based on Tc99m-octreotide scan findings and 2 more. Started Jun 2024; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
meningioma
Beyond the preview
Go deeper on IRCT20190623043986N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190623043986N1.